Lipponen P K, Eskelinen M J, Nordling S
Department of Pathology, University of Kuopio, Finland.
Br J Cancer. 1991 Dec;64(6):1139-44. doi: 10.1038/bjc.1991.478.
The predictive value of silver stained nucleolar organiser regions (AgNORs) was assessed in 229 patients with transitional cell bladder cancer followed up for over 10 years. The AgNORs were enumerated in pretreatment biopsy specimens. The AgNORs were related to clinical stage (T) (P = 0.0111), papillarity (P less than 0.0001), WHO grade (P less than 0.0001), DNA ploidy (P = 0.0010) and S-phase fraction (P less than 0.0001). Tumours presenting with pelvic lymph node involvement (P = 0.0085) or metastasis (P = 0.0780) at the time of diagnosis had more AgNORs than tumours confined to the bladder wall. Progression in T-, N- and M-categories (P = 0.0010-0.0030) was related to AgNORs and consequently they predicted bladder cancer related survival (P = 0.0005). The diploid tumours could be regrouped according to survival by AgNORs (P = 0.0001). In papillary tumours AgNORs predicted progression (P = 0.0110) and survival (P = 0.0038). In Ta-T1 tumours AgNORs predicted progression (P = 0.11) and survival (P = 0.0751) and also in T2-T3 tumours AgNORs contributed to survival significantly (P = 0.0039). The AgNORs subdivided WHO grade III tumours according to their ability to progress during the follow-up time (P = 0.0711). In a multivariate analysis AgNORs predicted progression independently in Ta-T1 category (P = 0.0165). AgNORs predicted recurrence free period like SPF (P = 0.0010). In conclusion, AgNORs are inferior to classic prognostic factors or DNA flow cytometric variables in muscle invasive bladder cancers whereas they have independent predictive value in superficial cancers.
对229例接受了超过10年随访的移行细胞膀胱癌患者,评估了银染核仁组成区(AgNORs)的预测价值。在预处理活检标本中对AgNORs进行计数。AgNORs与临床分期(T)(P = 0.0111)、乳头状(P < 0.0001)、世界卫生组织分级(P < 0.0001)、DNA倍体(P = 0.0010)和S期分数(P < 0.0001)相关。诊断时出现盆腔淋巴结受累(P = 0.0085)或转移(P = 0.0780)的肿瘤比局限于膀胱壁的肿瘤有更多的AgNORs。T、N和M分类的进展(P = 0.0010 - 0.0030)与AgNORs相关,因此它们可预测膀胱癌相关生存(P = 0.0005)。二倍体肿瘤可根据AgNORs的生存情况重新分组(P = 0.0001)。在乳头状肿瘤中,AgNORs可预测进展(P = 0.0110)和生存(P = 0.0038)。在Ta - T1肿瘤中,AgNORs可预测进展(P = 0.11)和生存(P = 0.0751),在T2 - T3肿瘤中,AgNORs对生存也有显著贡献(P = 0.0039)。AgNORs根据随访期间进展的能力对世界卫生组织III级肿瘤进行了细分(P = 0.0711)。在多变量分析中,AgNORs在Ta - T1分类中独立预测进展(P = 0.0165)。AgNORs预测无复发期与S期分数相似(P = 0.0010)。总之,在肌肉浸润性膀胱癌中,AgNORs不如经典预后因素或DNA流式细胞术变量,而在浅表性癌症中它们具有独立的预测价值。